[{"id":"7918a7a6-96c5-4624-85f3-798790d9ac5f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06703944","created_at":"2025-02-26T10:34:57.875Z","updated_at":"2025-02-26T10:34:57.875Z","phase":"","brief_title":"Risk Model for Metastasis Detection of Neuroblastoma","source_id_and_acronym":"NCT06703944","lead_sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","biomarkers":" PTPRC • NCAM1 • CD81","pipe":"","alterations":" ","tags":["PTPRC • NCAM1 • CD81"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 500","initiation":"Initiation: 12/01/2024","start_date":" 12/01/2024","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-12-04"},{"id":"7087c1cd-d2b0-4a2d-b876-81f1fb3057ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT04827745","created_at":"2022-04-25T15:54:32.118Z","updated_at":"2024-07-02T16:35:14.318Z","phase":"Phase 2","brief_title":"Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL","source_id_and_acronym":"NCT04827745","lead_sponsor":"University of Maryland, Baltimore","biomarkers":" CD81","pipe":" | ","alterations":" CD19 positive","tags":["CD81"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Blincyto (blinatumomab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 2","initiation":"Initiation: 06/11/2021","start_date":" 06/11/2021","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2024-03-18"},{"id":"7158f3c8-048e-44f4-84c4-9fea0fbb9783","acronym":"","url":"https://clinicaltrials.gov/study/NCT06282978","created_at":"2024-02-29T03:33:45.743Z","updated_at":"2024-07-02T16:35:16.129Z","phase":"Phase 2","brief_title":"Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes","source_id_and_acronym":"NCT06282978","lead_sponsor":"PETHEMA Foundation","biomarkers":" KIT • CD19 • CD38 • PTPRC • NCAM1 • CD27 • CD81","pipe":" | ","alterations":" CD38 expression • CD19 expression • NCAM1 expression • CD27 expression • CD5 overexpression • NCAM1 overexpression","tags":["KIT • CD19 • CD38 • PTPRC • NCAM1 • CD27 • CD81"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 expression • CD19 expression • NCAM1 expression • CD27 expression • CD5 overexpression • NCAM1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Elrexfio (elranatamab-bcmm)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 11/23/2023","start_date":" 11/23/2023","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2024-03-06"},{"id":"5a1f1c7f-5042-4321-ba07-3587d0d263c2","acronym":"PEP-C","url":"https://clinicaltrials.gov/study/NCT04053855","created_at":"2021-01-18T19:52:35.235Z","updated_at":"2024-07-02T16:35:31.587Z","phase":"","brief_title":"Evaluation of Urinary Exosomes Presence From Clear Cell Renal Cell Carcinoma","source_id_and_acronym":"NCT04053855 - PEP-C","lead_sponsor":"Centre Hospitalier Universitaire de Saint Etienne","biomarkers":" CA9 • CD9 • CD81","pipe":"","alterations":" ","tags":["CA9 • CD9 • CD81"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 01/29/2020","start_date":" 01/29/2020","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2023-10-26"}]